What Thrombocid (+Azulene) Treats: Main Uses and Benefits

---

The primary role of this topical preparation is to provide targeted symptomatic support across domains involving minor circulatory distress and localized trauma. The therapeutic domain is considered relevant for surface vascular support.

This medicine is considered relevant for conditions presenting with localized discomfort and swelling, and is applied in addressing symptom clusters that may become intense or disruptive. The key therapeutic areas include superficial venous disorders, feelings of heaviness and tightness in the legs, and supportive symptom management for superficial bruising (haematomas) following a blow or impact.

“This application supports patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.”

This support may assist with easing the overall symptom load, offering relief that helps patients cope more steadily with symptom fluctuations. It is often used during phases when symptoms become more noticeable, providing temporary symptomatic assistance.

---

Quick Fact: Supportive Symptomatic Relief for Superficial Bruising

Official Eligibility and Contraindications

The eligibility for using Thrombocid (+Azulene) topical preparation is strictly defined by government regulatory documents, focusing on patient status, age, and pre-existing conditions.

Absolute Contraindications

Use of this medicine is prohibited for specific populations as stated in the regulatory labeling:

• Patients with documented hypersensitivity or allergy to Pentosan Polysulfate Sodium, Azulene, or any other component in the formulation.
• Individuals diagnosed with significant coagulation disorders or an elevated hemorrhagic risk (bleeding tendency).
• Infants under 1 year of age are formally contraindicated due to insufficient data establishing safety and efficacy in this age group.

Population Eligibility and Restrictions

Category	Eligibility Rule
Age Groups	Approved for adults and children over 1 year (typically for superficial bruising).
Skin Condition	Application is prohibited on mucous membranes, open wounds, ulcers, or infected skin.
Pregnancy/Lactation	Not recommended or requires strict medical consultation before use.
Conditional Use	Patients with pre-existing venous issues (e.g., blood clots) must apply the preparation gently and without massage.

Interactions with other medicines and products

Regulatory information regarding Thrombocid (+Azulene) interactions is structured around the potential systemic effect of its active ingredient, Pentosan Polysulfate Sodium (PPS), even though the product is applied topically as a cream or ointment.

Pharmacodynamic Interactions

The primary documented interaction concern is pharmacodynamic reinforcement. Co-administration with certain medicinal products that influence coagulation is officially associated with an increased risk of a haemorrhagic event. This risk stems from the intrinsic weak anticoagulant property of PPS.

Interacting Medicinal Product Categories	Official Interaction Classification
Anticoagulants and Heparin derivatives	Risk of additive bleeding
Antiplatelet agents (e.g., Acetylsalicylic acid)	Risk of additive bleeding
Nonsteroidal Anti-inflammatory medicinal products (NSAIDs)	Risk of additive bleeding

Pharmacokinetic and Timing Constraints

No specific CYP-mediated or transporter interactions have been established for PPS according to regulatory findings. Additionally, the official labeling for the topical formulation does not mandate specific timing separation rules for administration with other medicines. No formal contraindicated combinations are listed specifically for the topical product.

Population-Specific Interaction Notes

Interaction notes specify that patients with underlying hepatic or renal impairment require monitoring. This caution is based on evidence that elimination of PPS may be impacted in these populations, which could potentially alter the overall pharmacokinetics of the ingredient.

Thrombocid contains Sodium Pentosan Polysulfate (SPPS), a semi-synthetic heparinoid that exerts its activity predominantly in the vascular and perivascular tissues following topical application. SPPS functions as a non-specific anticoagulant, primarily by interacting with components of the coagulation and fibrinolytic cascades.

At the molecular level, SPPS binds to the plasma protein antithrombin III (AT-III), inducing a conformational change that allosterically activates its inhibitory function towards activated clotting factors, including Factor Xa. This leads to an inhibition of thrombin generation and subsequent fibrin formation. Furthermore, SPPS is associated with the release of tissue plasminogen activator (t-PA) from the vascular endothelium, promoting the conversion of plasminogen to plasmin, which facilitates the proteolytic degradation of fibrin.

The system-level physiological consequence of this dual action is a modulation of local hemostasis, characterized by reduced coagulability and enhanced fibrinolytic capacity within the affected microcirculation. The added component, Azulene, a bicyclic sesquiterpene, contributes to the mechanism by inhibiting the cyclooxygenase-2 (COX-2) enzyme and regulating pro-inflammatory cytokine secretion (e.g., TNF-alpha, IL-6) in local macrophages, which introduces an anti-inflammatory cascade that modulates the perivascular inflammatory response.

The use of this topical preparation is intended as a localized, non-systemic intervention, restricted exclusively to cutaneous administration. The active component, Pentosan Polysulfate Sodium, is available in concentrations such as 1 mg/g and 5 mg/g (Forte).

---

Administration Protocol

The application route requires topical use, applied externally to the skin. The standard application involves placing a thin layer of the ointment or cream onto the affected area. This is performed 3 to 4 times per day. The technique generally involves gentle massage to aid distribution and absorption, but it is indicated that application be done without massage if the underlying condition is thrombotic in nature. The product must be applied only to intact skin, and contact with open wounds, ulcers, or mucous membranes must be strictly avoided.

Duration and Population Rules

This preparation is designated for short-term use. If the symptoms persist or worsen after 5 days of application, the course of treatment requires clinical re-evaluation, as prolonged or chronic use is restricted. The standard daily regimen is consistent for both adults and children over 1 year of age. Use is not recommended for children under 1 year due to insufficient data regarding this specific population.

Research Landscape Overview

Research has explored the use of this topical preparation across two main areas: superficial venous discomfort and superficial bruising (haematomas). The majority of the studies were evaluated in adult populations and primarily utilized Clinical Open-Label Trials and Observational Cohort Studies rather than large-scale, publicly indexed Randomized Controlled Trials (RCTs).

For localized symptoms such as heaviness and tightness in the legs, research examined patient-reported outcomes describing perceived discomfort over defined time intervals. Studies findings describe patterns observed in the studies regarding the short-term evolution of these reported discomfort scores. For superficial bruising, studies monitored outcomes related to the visual appearance of the bruise, such as the rate and extent of discoloration over time.

Study Design and Research Gaps

The available evidence for this topical combination is generally characterized as low in certainty, meaning evidence quality varies across studies. The studies primarily involve short observation periods, which means follow-up durations were limited and sufficient only for studying acute symptom episodes. Consequently, long-term effects are not fully established, and data for extended or repeated application are not available.

Furthermore, the research results apply only to the populations studied. Data for certain groups, such as pregnant individuals or those with significant underlying systemic health issues, remain insufficient. The evidence highlights what is known—and what is still uncertain—about the cream’s effects, emphasizing the need for robust comparative evidence.

Key Studies & References Prevention and Treatment of Phlebitis Secondary to the Insertion of a Peripheral Venous Catheter: A Scoping Review from a Nursing Perspective (Used for Context and Evidence Gap)

Common questions about Thrombocid (+Azulene) (FAQ)

---

Q: Does Thrombocid (+Azulene) interact with common pain relievers like ibuprofen?

Official labeling for this product includes Nonsteroidal Anti-inflammatory medicinal products (NSAIDs), such as ibuprofen, among those that may interact. Co-administration with NSAIDs is associated with a risk of pharmacodynamic reinforcement, or additive bleeding, due to the weak anticoagulant property of Pentosan Polysulfate Sodium (PPS), as described in official documents.

---

Q: How quickly should I expect to see an effect after using Thrombocid (+Azulene)?

Regulatory guidance describes this medicine as designated for short-term use. Official documents state that if symptoms persist or worsen after 5 days of application, the course of treatment requires clinical re-evaluation by a health professional. The product information does not specify an exact time frame (such as hours or days) for the onset of effect.

---

Q: Can I use Thrombocid (+Azulene) for long periods of time?

Regulatory documentation states that this preparation is designated for short-term use only. Prolonged or chronic use is not recommended by official guidelines. If symptoms persist beyond five days, the official guidelines recommend that the situation be clinically re-evaluated.

---

Q: What types of bruises is Thrombocid (+Azulene) typically used for?

According to official documentation, the product is indicated for the local symptomatic relief of superficial bruising (haematomas). This generally refers to bruises that are close to the skin's surface, typically resulting from impacts or minor trauma.

---

Q: Is Thrombocid (+Azulene) available without a prescription in most places?

Thrombocid (+Azulene) is generally described by government regulatory bodies as an Over-the-counter (OTC) medicine. This status indicates it is intended for non-prescription, local management of minor circulatory discomfort and bruising.

---

Q: What happens if I accidentally swallow a small amount of Thrombocid (+Azulene) gel?

Official documentation specifies the product is for external use (cutaneous administration) only. In case of accidental ingestion, especially by children, official safety information recommends consulting a national poison control center or seeking professional medical guidance.

---

Q: Is Thrombocid (+Azulene) a blood thinner?

The active ingredient, Pentosan Polysulfate Sodium (PPS), is a semi-synthetic heparinoid and is described as a non-specific anticoagulant. This means it is described as a non-specific anticoagulant with a weak anticoagulant property, as noted in the product’s description of activity.

---

Q: Is it appropriate to use Thrombocid (+Azulene) for varicose veins?

The product is officially indicated for the local symptomatic relief of superficial venous disorders in adults. These disorders may include symptoms such as heaviness or tightness that can be associated with venous issues like varicose veins.

---

Q: Does Thrombocid (+Azulene) help with swelling or just bruising?

The official indications include the relief of localized symptoms such as tightness, heaviness, and superficial bruising. While these conditions often involve swelling, 'swelling' or 'edema reduction' is not explicitly listed as a named indication in the official labeling.

---

Q: Has Thrombocid (+Azulene) been studied for athletic injuries?

Research has included studies on superficial bruising (haematomas), which are common in athletic activity. However, official documents do not categorize the product's use specifically for the broader term of 'athletic injuries,' such as sprains or strains.

---

Q: Do I need to rub the gel in completely when I apply Thrombocid (+Azulene)?

The administration protocol requires applying a thin layer of the product. The administration protocol generally involves gentle massage to aid distribution and penetration. However, the official documentation requires that application be done without massage if the underlying condition is thrombotic in nature, meaning the technique described depends on the intended use.

---

Q: Does using more Thrombocid (+Azulene) make it work faster?

The administration protocol requires applying a thin layer several times per day. Official labeling defines the standard application amount and frequency, and does not indicate that applying a larger amount will change the rate or degree of effect.

---

Q: Why is the drug sometimes referred to as 'Thrombocid' and sometimes 'Thrombocid with Azulene'?

The name variation is used to describe the product's composition. The active components are Pentosan Polysulfate Sodium (Thrombocid's main active ingredient) and Azulene, which is included to provide local soothing and anti-inflammatory action.

---

Q: Is the feeling of warmth after application described as common or uncommon?

The official safety profile focuses on localized adverse reactions such as itching and skin irritation. A feeling of warmth is not documented or classified as a known adverse reaction in the official product information.

How to Store and Dispose of Thrombocid Pomada

Official regulatory documents define specific, mandatory conditions for the storage and disposal of Thrombocid pomada (ointment) to ensure product stability and public safety.

Storage Requirements

• Temperature: The product must not be stored above 30, C (applicable to the 5 mg/g formulation).
• Container Integrity: The tube must be kept perfectly closed when not in use.
• Child Safety: The medicine must be kept out of the sight and reach of children.
• Shelf-Life: The pomada must not be used after the expiry date (CAD) printed on the packaging.

Disposal Instructions

Medicines must not be thrown into the drains or in the trash (household waste). Unused, expired product and its packaging must be handled according to local environmental regulations, typically by depositing them at a designated pharmaceutical waste collection point at the pharmacy.